The cytolytic amphipathic β(2,2)-amino acid LTX-401 induces DAMP release in melanoma cells and causes complete regression of B16 melanoma

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Eike, Liv Marie ^a   Mauseth, Brynjar ^a   Camilio, Ketil Andre ^a   Rekdal, Øystein ^a,b   Sveinbjørnsson, Baldur ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b LYTIX BIOPHARMA AS   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; CYTOTOXIC AGENT; DANGER ASSOCIATED MOLECULAR PATTERN MOLECULE; HIGH MOBILITY GROUP B1 PROTEIN; LTX 401; TUMOR PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; BETA ALANINE; CYTOTOXIN; HMGB1 PROTEIN, MOUSE; LTX-401;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CAUSAL ATTRIBUTION; CELL DEATH; CELL VACUOLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; LYSOSOME; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; RAT; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL SURVIVAL; DRUG EFFECTS; ERYTHROCYTE; HEMOLYSIS; IC50; INTRALESIONAL DRUG ADMINISTRATION; MELANOMA, EXPERIMENTAL; METABOLISM; REMISSION; SECRETION (PROCESS); SKIN NEOPLASMS; SYNTHESIS; TUMOR CELL LINE; ULTRASTRUCTURE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; BETA-ALANINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; CYTOTOXINS; ERYTHROCYTES; FEMALE; HEMOLYSIS; HMGB1 PROTEIN; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRALESIONAL; LYSOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RATS; REMISSION INDUCTION; SKIN NEOPLASMS; VACUOLES;

EID: 84979071499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148980     Document Type: Article

References (57)

1. Choi KY, Chow LN, Mookherjee N. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun. 2012; 4(4):361-70. doi: 10.1159/000336630 PMID: 22739631.
2. Hilchie AL, Wuerth K, Hancock RE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol. 2013; 9(12):761-8. doi: 10.1038/nchembio.1393 PMID: 24231617.
3. Midura-Nowaczek K, Markowska A. Antimicrobial peptides and their analogs: searching for new potential therapeutics. Perspect Medicin Chem. 2014; 6:73-80. doi: 10.4137/PMC.S13215 PMID: 25374459; PubMed Central PMCID: PMCPMC4213192.
4. Al-Benna S, Shai Y, Jacobsen F, Steinstraesser L. Oncolytic Activities of Host Defense Peptides. International Journal of Molecular Sciences. 2011; 12(11):8027-51. doi: 10.3390/ijms12118027 WOS:000297696100051. PMID: 22174648
5. Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjornsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother. 2014; 63(6):601-13. doi: 10.1007/s00262-014-1540-0 PMID: 24676901; PubMed Central PMCID: PMC4024132.
6. Maletzki C, Klier U, Marinkovic S, Klar E, Andra J, Linnebacher M. Host defense peptides for treatment of colorectal carcinoma-a comparative in vitro and in vivo analysis. Oncotarget. 2014; 5(12):4467-79. doi: 10.18632/oncotarget.2039 PMID: 24962950; PubMed Central PMCID: PMCPMC4147338.
7. Szczepanski C, Tenstad O, Baumann A, Martinez A, Myklebust R, Bjerkvig R, et al. Identification of a novel lytic peptide for the treatment of solid tumours. Genes Cancer. 2014; 5(5-6):186-200. PMID: 25061502; PubMed Central PMCID: PMCPMC4104761.
8. Yang N, Lejon T, Rekdal O. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci. 2003; 9(5):300-11. Epub 2003/06/14. doi: 10.1002/psc.457 PMID: 12803496.
9. Strom MB, Haug BE, Skar ML, Stensen W, Stiberg T, Svendsen JS. The pharmacophore of short cationic antibacterial peptides. J Med Chem. 2003; 46(9):1567-70. doi: 10.1021/jm0340039 PMID: 12699374.
10. Shimoyama Y, Kubota T, Watanabe M, Ishibiki K, Abe O. Predictability of in vivo chemosensitivity by in vitro MTT assay with reference to the clonogenic assay. J Surg Oncol. 1989; 41(1):12-8. PMID: 2716329.
11. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 2002; 22(5):2703-10. WOS:000180132200026. PMID: 12529985
12. Griffith G. Fixation for Fine Structure Preseravation and Immunohistochemistry. 1993.
13. Pokrovskaya ID, Szwedo JW, Goodwin A, Lupashina TV, Nagarajan UM, Lupashin VV. Chlamydia trachomatis hijacks intra-Golgi COG complex-dependent vesicle trafficking pathway. Cell Microbiol. 2012; 14(5):656-68. doi: 10.1111/j.1462-5822.2012.01747.x PMID: 22233276; PubMed Central PMCID: PMCPMC3330190.
14. Hayat M. Stain and Cytochemical Methods. 1993.
15. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013; 4:e631. doi: 10.1038/cddis.2013.156 PMID: 23681226; PubMed Central PMCID: PMCPMC3674363.
16. Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC. Mitochondrial damageassociated molecular patterns and vascular function. Eur Heart J. 2014; 35(18):1172-7. Epub 2014/02/27. doi: 10.1093/eurheartj/ehu047 PMID: 24569027; PubMed Central PMCID: PMCPmc4012709.
17. Pullerits R, Bokarewa M, Jonsson IM, Verdrengh M, Tarkowski A. Extracellular cytochrome c, a mitochondrial apoptosis-related protein, induces arthritis. Rheumatology (Oxford). 2005; 44(1):32-9. doi: 10.1093/rheumatology/keh406 PMID: 15367748.
18. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014; 21(1):39-49. doi: 10.1038/cdd.2013.84 PMID: 23832118
19. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy. 2012; 8(3):413-5. doi: 10.4161/auto.19009 PMID: 22361584.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230.
21. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31(1):51-72. doi: 10.1146/annurev-immunol-032712-100008 PMID: 23157435.
22. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, et al. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014; 3(1):e27878. doi: 10.4161/onci.27878 PMID: 24800173; PubMed Central PMCID: PMCPMC4008470.
23. Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjornsson B, Rekdal O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother. 2010; 59(8):1285-94. doi: 10.1007/s00262-010-0857-6 PMID: 20422410.
24. Camilio KA, Rekdal O, Sveinbjornsson B. LTX-315 (Oncopore): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology. 2014; 3:e29181. doi: 10.4161/onci.29181 PMID: 25083333; PubMed Central PMCID: PMCPMC4108458.
25. Singh M, Overwijk WW. Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother. 2015; 64(7):911-21. doi: 10.1007/s00262-015-1727-z PMID: 26050024.
26. Hansen T, Ausbacher D, Zachariassen ZG, Anderssen T, Havelkova M, Strom MB. Anticancer activity of small amphipathic beta(2),(2)-amino acid derivatives. Eur J Med Chem. 2012; 58:22-9. doi: 10.1016/j.ejmech.2012.09.048 PMID: 23085771.
27. Yang N, Stensen W, Svendsen JS, Rekdal O. Enhanced antitumor activity and selectivity of lactoferrinderived peptides. J Pept Res. 2002; 60(4):187-97. PMID: 12366526.
28. Yang N, Strom MB, Mekonnen SM, Svendsen JS, Rekdal O. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci. 2004; 10(1):37-46. Epub 2004/02/13. doi: 10.1002/psc.470 PMID: 14959890.
29. Huang YB, He LY, Jiang HY, Chen YX. Role of helicity on the anticancer mechanism of action of cationic-helical peptides. Int J Mol Sci. 2012; 13(6):6849-62. doi: 10.3390/ijms13066849 PMID: 22837667; PubMed Central PMCID: PMCPMC3397499.
30. Huang YB, Wang XF, Wang HY, Liu Y, Chen Y. Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. Mol Cancer Ther. 2011; 10 (3):416-26. doi: 10.1158/1535-7163.MCT-10-0811 PMID: 21252288.
31. ATCC. Available: http://www.lgcstandards-atcc.org/products/all/CRL-6323.aspx?geo-country=no.
32. Chiang EY, Henson M, Stroynowski I. Correction of defects responsible for impaired Qa-2 class Ib MHC expression on melanoma cells protects mice from tumor growth. J Immunol. 2003; 170(9):4515-23. PMID: 12707328.
33. Palombo F, Focaccetti C, Barnaba V. Therapeutic implications of immunogenic cell death in human cancer. Front Immunol. 2014; 4:503. doi: 10.3389/fimmu.2013.00503 PMID: 24432020; PubMed Central PMCID: PMCPMC3880935.
34. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: Indispensable for therapeutic success? J Clin Invest. 2008; 118(6):1991-2001. doi: 10.1172/JCI35180 PMID: 18523649; PubMed Central PMCID: PMC2396905.
35. Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, et al. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal. 2014; 20(7):1098-116. Epub 2013/02/12. doi: 10.1089/ars.2012.5133 PMID: 23394620.
36. Bianchi ME. Killing cancer cells, twice with one shot. Cell Death Differ. 2014; 21(1):1-2. doi: 10.1038/cdd.2013.147 PMID: 24317270; PubMed Central PMCID: PMCPMC3857630.
37. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011; 30(1):61-9. doi: 10.1007/s10555-011-9273-4 PMID: 21249425.
38. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5(4):331-42. doi: 10.1038/nri1594 PMID: 15803152.
39. Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799(1-2):131-40. doi: 10.1016/j.bbagrm.2009.11.014 PMID: 20123075; PubMed Central PMCID: PMCPMC2818552.
40. Guerriero JL, Ditsworth D, Catanzaro JM, Sabino G, Furie MB, Kew RR, et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol. 2011; 186(6):3517-26. doi: 10.4049/jimmunol.1003267 PMID: 21300822; PubMed Central PMCID: PMCPMC3066027.
41. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ. 2008; 15(1):21-8. doi: 10.1038/sj.cdd.4402266 PMID: 17992190.
42. Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A. DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol. 2009; 86(3):549-55. doi: 10.1189/jlb. 1008598 PMID: 19564570.
43. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med. 2012; 18:250-9. Epub 2011/11/23. doi: 10.2119/molmed.2011.00389 PMID: 22105604; PubMed Central PMCID: PMC3324950.
44. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009; 461(7261):282-6. doi: 10.1038/nature08296 PMID: 19741708; PubMed Central PMCID: PMCPMC2851546.
45. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010; 70(3):855-8. doi: 10.1158/0008-5472.CAN-09-3566 PMID: 20086177.
46. Ayna G, Krysko DV, Kaczmarek A, Petrovski G, Vandenabeele P, Fesus L. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. Plos One. 2012; 7(6):e40069. doi: 10.1371/journal.pone.0040069 PMID: 22768222; PubMed Central PMCID: PMCPMC3386917.
47. Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother. 2012; 35(4):299-308. doi: 10.1097/CJI.0b013e3182518e83 PMID: 22495387; PubMed Central PMCID: PMCPMC3331796.
48. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000; 2(3):156-62. doi: 10.1038/35004029 PMID: 10707086.
49. Jemmerson R, LaPlante B, Treeful A. Release of intact, monomeric cytochrome c from apoptotic and necrotic cells. Cell Death Differ. 2002; 9(5):538-48. doi: 10.1038/sj/cdd/4400981 PMID: 11973612.
50. Adachi N, Hirota M, Hamaguchi M, Okamoto K, Watanabe K, Endo F. Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome. Clin Chim Acta. 2004; 342(1-2):127-36. doi: 10.1016/j.cccn.2003.12.011 PMID: 15026273.
51. Ausbacher D, Svineng G, Hansen T, Strom MB. Anticancer mechanisms of action of two small amphipathic beta(2,2)-amino acid derivatives derived from antimicrobial peptides. Biochim Biophys Acta. 2012; 1818(11):2917-25. doi: 10.1016/j.bbamem.2012.07.005 PMID: 22820149.
52. Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol. 2013; 190(1):469-78. doi: 10.4049/jimmunol.1201209 PMID: 23225891; PubMed Central PMCID: PMCPMC3529845.
53. Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015; 64(8):999-1009. doi: 10.1007/s00262-015-1704-6 PMID: 25971540.
54. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014; 14(8):559-67. doi: 10.1038/nrc3770 PMID: 24990523.
55. Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother. 2015; 11(8):1901-9. doi: 10.1080/21645515.2015.1049779 PMID: 26055074; PubMed Central PMCID: PMCPMC4635874.
56. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res. 2008; 14(22):7358-66. doi: 10.1158/1078-0432.CCR-08-0831 PMID: 19010851; PubMed Central PMCID: PMCPMC2701231.
57. Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, et al. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. J Transl Med. 2015; 13:139. doi: 10.1186/s12967-015-0473-5 PMID: 25933939; PubMed Central PMCID: PMCPMC4438625.